Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07829029) titled 'Ancillary Nocturnal Urinary Symptoms Analyses for TRIUMPH' on Sept. 14.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).
Primary Sponsor: University of California, San Francisco
Condition:
Nocturia
Nocturnal Urinary Incontinence
Intervention:
Drug: TolterodineTartrate ER
Drug: Mirabegron
Recruitment Status: Recruiting
Phase: Phase 4
Date of First Enrollment: October 4, 2022
Target Sample Size: 270
Countries of Recruitment:
United States
To know more, vis...